Biogen Acquiring Pfizer’s Investigational Therapy PF-05251749 for Alzheimer’s, Parkinson’s Symptoms

Biogen Acquiring Pfizer’s Investigational Therapy PF-05251749 for Alzheimer’s, Parkinson’s Symptoms
Biogen is acquiring from Pfizer investigational therapy PF-05251749, a small molecule being developed to treat sundowning in Alzheimer’s disease and irregular sleep wake rhythm disorder (ISWRD) in Parkinson's disease. The company plans to begin a Phase 1b clinical trial by the end of this year, according to a press release. PF-05251749 is aimed at regulating circadian rhythms, the changes the body goes through over the course of a day. The body's internal timekeeping systems help regulate the daily cycles that signal, for example, hunger and sleepiness. In people with neurological conditions such as Alzheimer's and Parkinson's, these systems can become disrupted, with far-reaching consequences. “Many patients with Alzheimer’s and Parkinson’s suffer from debilitating sleep disorders and agitation, and we believe that the regulation of the circadian rhythm may hold promise in addressing these challenging behavioral and neurological symptoms,” Alfred Sandrock Jr., MD, PhD, Biogen's executive vice president of research and development and chief m
Subscribe or to access all post and page content.